Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
Go back to Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen| Rider Explorations, Inc. (NASDAQ: REPL) | Delayed: 15.04 -0.25 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.29 | 52 Week High | $1.45 | |||
| Open | $15.22 | 52 Week Low | $0.50 | |||
| Day High | $15.33 | P/E | N/A | |||
| Day Low | $14.80 | EPS | $0.00 | |||
| Volume | 910,230 | |||||
